Table I.
Target tissue + condition | Species | Model | Vector | End points | Reference |
---|---|---|---|---|---|
Aorta + heart failure | rat | in vivo IV | Ad | Restored NO levels and responses to acetylcholine; decreased levels of and peroxynitrite | 16 |
+ hypercholesterolemia | mouse | in vivo IV | Ad | Did not affect atherogenesis | 18 |
+ aging | rat | in vivo IV | Ad | Decreased vascular | 19 |
+ spontaneous hypertension | rat | in vivo IV | Ad | Decreased levels of and nitrotyrosine | 20 |
+ LPS treatment | rat | in vivo IV | Ad | Decreased and LPS-induced adhesion of leukocytes to aortic endothelium | 22 |
+ balloon denudation | rabbit | in vivo local delivery | Ad | Decreased , neointimal formation, and macrophage infiltration; IV gene transfer did not decrease restenosis | 17 |
Carotid artery + spontaneous hypertension | rat | in vivo IV | Ad | Increased basal NO levels and responses to acetylcholine | 20 |
+ spontaneous hypertension | rat | in vivo IV | Ad | Increased sodium balance and relaxation to acetylcholine; decreased mean arterial pressure | 21 |
+ stroke-prone, spontaneous hypertension | rat | in vivo IV | Ad | Increased NO availability; improved endothelial function | 23 |
Basilar artery + subarachnoid hemorrhage | dog | in vivo cisterna magna | Ad | Failed to prevent delayed cerebral vasospasm | 24 |
Brain | rabbit | in vivo cisterna magna | Ad | Increased SOD activity in cerebrospinal fluid | 25 |
Basilar artery + subarachnoid hemorrhage | rabbit | in vivo cisterna magna | Ad | Decreased cerebral vasospasm | 26 |
Portal vein + acute liver injury | mouse | in vivo IV | ecSOD lipoplexes | Increased serum SOD activity and liver glutathione levels; decreased lipid peroxidation | 27 |
Knee joint + antigen-induced arthritis | rat | ex vivo | ecSOD-expressing synoviocytes | Decreased joint swelling and gelatinase activity; decreased infiltration of inflammatory cells into the synovial membrane | 28 |
+ collagen-induced arthritis | mouse | ex vivo | ecSOD-expressing fibroblasts | Decreased mononuclear cell infiltration and synovial proliferation; improved histologic abnormalities, including destruction of cartilage and bone | 29 |
Heart + myocardial infarction | rabbit | in vivo IV | Ad | Markedly decreased infarct size | 30 |
+ myocardial stunning | rabbit | in vivo IV | Ad | Increased ecSOD levels in the liver; improved left ventricular wall motion | 31 |
Liver + paracetamol-induced damage | mouse | in vivo IV | Ad | Significantly attenuated release of liver enzymes and inhibited necrosis and apoptosis | 18 |
+ ischemia/reperfusion- induced liver injury | mouse | in vivo IV | polylipid nanoparticles | Increased SOD activity and decreased levels and oxidative stress in liver; decreased enzyme release and improved liver histology | 32 |
Cavernosum + diabetes | rat | in vivo IV | Ad | Decreased levels | 33 |
Bowel + colitis | mouse | ex vivo | ecSOD-expressing fibroblasts | Increased chance of survival | 34 |
Abbreviations: Ad, adenovirus; IV, intravenous; LPS, lipopolysaccharide.